Jordyn Tarazi

Before joining ABio-X, Jordyn was the Director of Investor Relations at CohBar, Inc., a NASDAQ listed clinical-stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases. While at CohBar, she led and built the investor relations, corporate communications, business development, and internal communication functions from an academic, founder run company to a mature publicly traded company. Previously, she was the Director of Investor Relations at NASDAQ listed Fluent, Inc. and OncoSec Medical. As the department head, she created successful investor relations and corporate communication functions, attracting top tier institutions and sell side research analysts. She started her career in investment banking at Rodman & Renshaw, where she assisted with raising in excess of $1 billion for a number of public and private companies utilizing various structures. Jordyn graduated Summa Cum Laude from DePaul University.